Roivant Sciences Files 8-K

Ticker: ROIV · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1635088

Sentiment: neutral

Topics: corporate-disclosure, regulatory-filing

TL;DR

Roivant Sciences filed an 8-K on 9/17/25 covering Reg FD, other events, and financials.

AI Summary

Roivant Sciences Ltd. filed an 8-K on September 17, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing details the company's principal executive offices located in London, United Kingdom, and its fiscal year end of March 31st.

Why It Matters

This 8-K filing provides an update on Roivant Sciences' corporate activities and disclosures, which is important for investors to stay informed about the company's regulatory compliance and operational events.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.

Key Numbers

Key Players & Entities

FAQ

What specific events are detailed in the Regulation FD Disclosure section?

The filing indicates a Regulation FD Disclosure but does not provide specific details within the provided text.

What are the 'Other Events' reported by Roivant Sciences?

The filing lists 'Other Events' as a category but does not specify the nature of these events in the provided text.

What type of financial statements and exhibits are included in this filing?

The filing mentions 'Financial Statements and Exhibits' but does not specify their content in the provided text.

Where are Roivant Sciences' principal executive offices located?

Roivant Sciences' principal executive offices are located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom.

What is Roivant Sciences' fiscal year end?

Roivant Sciences' fiscal year ends on March 31st.

Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 9.2 · Accepted 2025-09-17 07:45:44

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 17, 2025, Roivant Sciences Ltd. (the "Company") issued a press release announcing positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis at its subsidiary Priovant Therapeutics. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or Securities Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01

Item 8.01 Other Events. On September 17, 2025, the Company posted a presentation regarding the results from the Phase 3 VALOR study on the "Events & Presentations" page of its investor relations website at https://investor.roivant.com and will host a conference call and webcast to discuss the results at 8:00 a.m. E.D.T. on September 17, 2025. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The contents of the Company's website referenced in this Current Report on Form 8-K are not incorporated into this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release, dated September 17, 2025. 99.2 Presentation, dated September 17, 2025. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory Dated: September 17, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing